ViaCyte Lands $10,600,000 Series C Financing

  • Feed Type
  • Date
    7/10/2013
  • Company Name
    ViaCyte
  • Mailing Address
    3550 General Atomics Court San Diego, CA 92121
  • Company Description
    ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device.
  • Website
    http://www.viacyte.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $10,600,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The Company will use the funds to pursue clinical development of VC-01. VC-01 is a development-stage product that consists of pancreatic precursor cells (designated PEC-01) manufactured through directed differentiation of stem cells sourced from a proprietary human embryonic stem cell line, and encapsulated in a proprietary, immune protective medical device (the ENCAPTRA device).
  • M&A Terms
  • Venture Investor
    Johnson & Johnson Development Corporation
  • Venture Investor
    Sanderling Ventures
  • Venture Investor
    Asset Management Ventures